Chronic Myelomonocytic Leukemia Completed Phase 2 Trials for Azacitidine (DB00928)

Also known as: Chronic myelomonocytic leukaemia / Chronic myelomonocytic leukemia with failed remission / Leukemia, Myelomonocytic, Chronic

IndicationStatusPhase
DBCOND0028572 (Chronic Myelomonocytic Leukemia)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00313586Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaTreatment
NCT01048034Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)Treatment
NCT01083706Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell TransplantTreatment
NCT01350947A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic LeukemiaTreatment